mRNA-1273 and BNT162b2 mRNA vaccines have reduced neutralizing activity against the SARS-CoV-2 omicron variant.
mRNA-1273 and BNT162b2 mRNA vaccines have reduced neutralizing activity against the SARS-CoV-2 omicron variant.
复制标题
DOI：
10.1016/j.xcrm.2022.100529
复制
发表时间：
2022-02-15
期刊：
影响因子：
--
通讯作者：
Suthar MS
中科院分区：
文献类型：
--
作者：
Edara VV;Manning KE;Ellis M;Lai L;Moore KM;Foster SL;Floyd K;Davis-Gardner ME;Mantus G;Nyhoff LE;Bechnak S;Alaaeddine G;Naji A;Samaha H;Lee M;Bristow L;Gagne M;Roberts-Torres J;Henry AR;Godbole S;Grakoui A;Saxton M;Piantadosi A;Waggoner JJ;Douek DC;Rouphael N;Wrammert J;Suthar MS
严重急性呼吸综合征冠状病毒2(SARS-CoV-2)Omicron变异株出现在2021年11月，由尖峰内的几个突变组成。在活体病毒实验中，我们使用来自mRNA疫苗接种的个体的血清来测量中和奥美康的活性。在一系列初级疫苗接种后2-4周，我们观察到对奥美康的中和活性降低了30倍。在最初的两剂疫苗接种六个月后，来自未接种疫苗的受试者的血清没有显示出对奥美康的中和活性。相比之下，新冠肺炎恢复的个体在接种初级系列疫苗6个月后显示出22倍的减少，大多数受试者保留了中和抗体反应。在幼稚的个体中，在加强注射(第三剂)后，我们观察到对奥美康的中和活性降低了14倍，超过90%的受试者表现出中和活性。这些发现表明，需要第三剂疫苗才能对奥米克隆变种提供强大的中和抗体反应。奥美康对疫苗诱导的中和抗体(NAB)效价有显著影响。未接种疫苗的个体在6个月后失去了针对奥米克隆变种的NAB滴度。在本研究中，需要加强免疫(第三剂)以保持对奥米克隆的中和活性。报道称，在初级系列(最初两剂)mRNA疫苗接种6个月后，大多数受试者失去了针对奥米克隆的可检测到的中和抗体效价。数据表明，为了维持对奥美康的中和活性，第三剂增强剂是必要的。
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) omicron variant emerged in November 2021 and consists of several mutations within the spike. We use serum from mRNA-vaccinated individuals to measure neutralization activity against omicron in a live-virus assay. At 2–4 weeks after a primary series of vaccinations, we observe a 30-fold reduction in neutralizing activity against omicron. Six months after the initial two-vaccine doses, sera from naive vaccinated subjects show no neutralizing activity against omicron. In contrast, COVID-19-recovered individuals 6 months after receiving the primary series of vaccinations show a 22-fold reduction, with the majority of the subjects retaining neutralizing antibody responses. In naive individuals following a booster shot (third dose), we observe a 14-fold reduction in neutralizing activity against omicron, and over 90% of subjects show neutralizing activity. These findings show that a third dose is required to provide robust neutralizing antibody responses against the omicron variant. Omicron has a significant impact on vaccine-induced neutralizing antibody (nAb) titers Naive vaccinated individuals lost nAb titers against omicron variant after 6 months A booster (third dose) is required to maintain neutralizing activity against omicron Here in this study, Edara et al. report that 6 months after the primary series (initial two doses) of mRNA vaccination, the majority of the subjects lost detectable neutralizing antibody titers against omicron. The data suggest that a third booster dose is necessary to sustain neutralizing activity against omicron.
登录
查看更多内容
DOI：
10.1056/nejmoa2113017
发表时间：
2021-11-04
期刊：
The New England journal of medicine
影响因子：
--
作者：
El Sahly HM;Baden LR;Essink B;Doblecki-Lewis S;Martin JM;Anderson EJ;Campbell TB;Clark J;Jackson LA;Fichtenbaum CJ;Zervos M;Rankin B;Eder F;Feldman G;Kennelly C;Han-Conrad L;Levin M;Neuzil KM;Corey L;Gilbert P;Janes H;Follmann D;Marovich M;Polakowski L;Mascola JR;Ledgerwood JE;Graham BS;August A;Clouting H;Deng W;Han S;Leav B;Manzo D;Pajon R;Schödel F;Tomassini JE;Zhou H;Miller J;COVE Study Group
通讯作者：
COVE Study Group
DOI：
10.1056/nejmoa2035389
发表时间：
2021-02-04
期刊：
The New England journal of medicine
影响因子：
--
作者：
Baden LR;El Sahly HM;Essink B;Kotloff K;Frey S;Novak R;Diemert D;Spector SA;Rouphael N;Creech CB;McGettigan J;Khetan S;Segall N;Solis J;Brosz A;Fierro C;Schwartz H;Neuzil K;Corey L;Gilbert P;Janes H;Follmann D;Marovich M;Mascola J;Polakowski L;Ledgerwood J;Graham BS;Bennett H;Pajon R;Knightly C;Leav B;Deng W;Zhou H;Han S;Ivarsson M;Miller J;Zaks T;COVE Study Group
通讯作者：
COVE Study Group
影响因子：
3.8
作者：
Katzelnick, Leah C.;Escoto, Ana Coello;Cummings, Derek A. T.
通讯作者：
Cummings, Derek A. T.
DOI：
10.15585/mmwr.mm7050e1
发表时间：
2021-12-17
期刊：
MMWR. Morbidity and mortality weekly report
影响因子：
--
作者：
CDC COVID-19 Response Team
通讯作者：
CDC COVID-19 Response Team
影响因子：
30.3
作者：
Xie, Xuping;Muruato, Antonio;Shi, Pei-Yong
通讯作者：
Shi, Pei-Yong